Articles tagged with Hdac Inhibitors
A team of researchers from Penn State has identified HDAC3 as a key contributor to age-related impairments in memory updating. When blocked, older mice performed similarly to their younger counterparts, suggesting potential therapeutic targets for improving cognitive flexibility in old age.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
New therapies aim to strengthen the body's immune responses and restore antimicrobial functions to combat TB. Researchers have identified small molecule compounds that reduce Mtb growth inside immune cells by up to 50-75%, suggesting a potential complement to standard therapy.
Researchers investigated the mechanism of 2′, 5′-Dihydroxyacetophenone (DHAP) in cytokine storm and found it inhibits inflammatory factors and increases Hdac1 protein stability, alleviating symptoms.
Researchers have discovered that certain volatile compounds emitted by microbes and food can alter epigenetic states in neurons and other eukaryotic cells. Exposure to these compounds can slow down neurodegeneration and cancer, while also affecting plant growth and responses to stress.
Researchers at Baylor College of Medicine have developed a novel combination therapy that produced encouraging results in animal models. The therapy, which includes an inhibitor of the enzyme histone deacetylase (HDAC), showed significant tumor shrinkage and reduced alpha fetoprotein levels after just one week of treatment.
A novel three-drug combination of an HDAC inhibitor with two types of immunotherapy achieved a 25% overall response rate and 50% progression-free survival in women with advanced HER2-negative breast cancer. Patients with triple-negative breast cancer had a higher response rate, highlighting the need for further clinical evaluation.
Scientists found that short-chain fatty acids produced by gut bacteria suppress allergic reactions by modulating mast cell activation and epigenetic modifications. This study provides new insights into the relationship between diet and immune system regulation, with potential applications in allergy treatment.
Researchers at Salk Institute discovered how anti-cancer drugs can prevent fibroblast activation, a protective barrier around pancreatic tumors. The therapy reduces tumor growth and slows disease progression in mice and human patients, offering a promising treatment for pancreatic cancer.
A team of researchers at Massachusetts General Hospital has identified a new small molecule inhibitor, PB118, that significantly reduces Alzheimer's disease neuropathology. The inhibitor targets histone deacetylase 6 (HDAC6), which is overexpressed in the brain of AD patients.
A CU School of Medicine research team has identified histone deacetylase 11 (HDAC11) as a potential target for treating obesity and metabolic disease. Inhibiting HDAC11 stimulates the expression of uncoupling protein 1, inducing fat cells to expend energy and potentially overcoming catecholamine resistance.
A team of researchers is exploring the potential of HDAC inhibitors to treat sickle cell disease by reactivating the fetal hemoglobin gene. Early evidence suggests that panobinostat, a specific inhibitor, can increase fetal hemoglobin levels in red blood cells and mouse models.
A Medical University of South Carolina research team has discovered that HDAC1 plays a crucial role in packing DNA around histones, which can help target cancer cells with inhibitors. The novel egg extract system allows researchers to study DNA packing in real-time, outside of a cell.
Researchers identified CUDC907 as a dual phosphoinositide-3 kinase/histone deacetylase inhibitor that promotes apoptosis in NF2 schwannoma cells. The compound reduced viability and induced cell cycle arrest in human merlin deficient Schwann cell models.
Researchers found reduced levels of Histone Deacetylase I (HDAC I) in the brains of patients with Alzheimer's disease, linked to deleterious effects of misfolded beta-amyloid and tau proteins. HDAC inhibitors, currently being tested against mild Alzheimer's disease, may be harming patients rather than helping them.
Researchers used chemoproteomics to profile 53 HDAC drugs and found many had additional targets beyond their intended HDACs. The study identified MBLAC2 as a common off-target protein that affects extracellular vesicle accumulation.
Researchers at Boston Children's Hospital propose using an existing drug to prevent NET formation, which can lead to severe inflammation in conditions like COVID-19, sepsis, and ARDS. The study shows that ricolinostat inhibits histone deacetylases, reducing NET formation and inflammation.
A new study has identified RNF5 as a key player in acute myeloid leukemia, regulating gene expression through its interaction with protein RBBP4. Inhibiting RNF5 may improve treatment outcomes for AML patients by increasing sensitivity to existing targeted therapies.
A phase II clinical trial of remetinostat gel found a 69.7% response rate to the topical treatment, with complete responses observed across multiple BCC subtypes, and a durable response in nodular BCCs.
The June edition of SLAS Discovery features the cover article on developing high-throughput biochemical assays to assess small molecule impact on SARS-CoV-2 nonstructural protein 14. The issue also includes nine original research articles, covering topics such as HIV latency reversal, kinase inhibitors, and drug combination screening.
In a phase I clinical trial, vorinostat in combination with sirolimus or everolimus demonstrated improved outcomes for patients with heavily pretreated relapsed/refractory Hodgkin lymphoma. The treatment combination achieved an objective response rate of 55% and median progression-free survival of 5.3 months.
Researchers discovered that combining an ATM inhibitor with a histone deacetylase inhibitor increases apoptosis and decreases p21 expression, allowing for more effective cancer treatment. The study found that the ATM inhibitor nullifies the HDAC inhibitor's ability to induce p21, leading to synergistic effects.
A Mount Sinai research team has identified the scaffolding protein histone deacetylase 3 (HDAC3) as essential for proper skin development and barrier formation. Mice lacking HDAC3 in the epidermis fail to develop a functional skin barrier, leading to dehydration and death shortly after birth.
A University of Colorado Cancer Center study reveals that combining immunotherapy with histone deacetylase (HDAC) inhibition sensitizes cancers to anti-PD1 therapy. HDAC inhibitors upregulate major histocompatibility complex (MHC) proteins, presenting antigens to T cells and making them effective against cancer cells.
A combination of HDAC inhibitor entinostat and pembrolizumab showed clinical responses in patients with melanoma that had progressed on prior anti-PD-1 treatment. The study suggests that adding HDAC inhibition to anti-PD-1 therapy may increase the efficacy of immunotherapy by modulating the immune system.
A phase III trial demonstrated that chidamide, an HDAC inhibitor, improves progression-free survival compared to placebo plus exemestane in patients with hormone receptor-positive advanced breast cancer. Serious adverse events were reported, but the treatment regimen was generally well-tolerated.
Studies with rodent models show reduced anxiety and improved brain function with early treatment using the histone deacetylase inhibitor LBH589. This approach may offer a new therapeutic strategy for Huntington disease.
Researchers found that HDAC3 inhibitors increase expression of aquaporin-3, a channel that transports glycerin, helping to improve skin health and reducing inflammation. The study's findings suggest that HDAC inhibitors could be an effective therapy for psoriasis.
Researchers have found a class of drugs, histone deacetylase inhibitors, can eliminate kidney toxicity caused by cisplatin, a widely used chemotherapy agent. The combination therapy shows promise in reducing inflammation and cell death in the kidneys.
New study reveals that histone deacetylase 6 inhibition improves the ability of oncolytic herpes simplex virus type 1 to kill glioma cells. HDAC inhibitors increase viral trafficking to the nucleus, leading to increased replication and tumor cell death.
Mayo researchers found that class II HDAC inhibitors signal through a newly discovered pathway to promote synergy with chemotherapy treatment in anaplastic thyroid cancer. The study identified vorinostat and belinostat as effective agents, which can increase activity of RhoB, a tumor suppressor and stimulate cell death.
Research suggests that HDAC inhibitors used to flush out HIV from infected cells may also suppress the immune system's ability to target and eliminate these cells. This finding has significant implications for the development of effective HIV eradication strategies.
Researchers at the University of Gothenburg have developed a new combination treatment for cancer using the molecules RVX2135 and HDAC inhibitors. The treatment has been shown to increase survival rates in mice with MYC-driven lymphoma by activating similar genes as existing cancer treatments.
Researchers at the University of Pennsylvania School of Medicine found that HDAC3 can repress gene expression and prevent fatty liver even without enzyme activity. This study challenges the molecular targets of HDAC inhibitors, warranting reassessment of their mechanisms.
A significant scientific discovery has been made in the fight against Huntington's disease, identifying specific enzymes called HDACs as positive agents for the mutation that underlies the disorder. Blocking these enzymes with experimental drugs greatly reduces the risk of further mutation.
Researchers have discovered a drug that can alter the DNA of uveal melanoma cells, rendering them less aggressive. The treatment, known as histone deacetylase inhibitors, may slow or prevent tumor growth in patients with metastatic eye cancer.
Scientists at Oregon State University have confirmed the safety and cancer-targeting ability of sulforaphane in a new study. Sulforaphane selectively kills cancer cells while leaving healthy prostate cells untouched, suggesting it could be used for cancer prevention and treatment.
Scientists at Notre Dame and Cornell have made a breakthrough in understanding the genetic disorder Niemann-Pick Type C, which affects brain cells and causes devastating symptoms. Using histone deacetylase inhibitors, researchers were able to correct the damage done by the genetic flaw and restore normal cell function.
Researchers at Weill Cornell Medical College have identified a potential new combinatorial therapy for diffuse large B cell lymphoma, the most common form of non-Hodgkin lymphoma. Combining an inhibitor of BCL6 with either HDAC proteins or Hsp90 protein enhanced killing of cancer cells in vitro and suppressed tumor growth in mice.
Research suggests that epigenetics plays a key role in the development of degenerative diseases. Environmental influences can alter gene expression, which can be passed on to offspring and impact life and death. HDAC inhibitors, found in foods like broccoli and garlic, may help prevent cancer by silencing tumor suppressor genes.
Researchers from Oregon State University are exploring the link between epigenetics, diet, and disease prevention. They found that HDAC inhibitors, found in foods like broccoli and garlic, can stop degenerative processes and turn off tumor suppressor genes.
Researchers have developed a 'shock and kill' technique to target and eliminate latent HIV-1 cells in the body. By combining histone deacetylase inhibitors with oxidative stress, infected cells can be induced to produce toxic compounds leading to their death.
A team led by Li-Huei Tsai has pinpointed the exact gene responsible for reversing Alzheimer's-like symptoms in mice. The researchers found that drugs targeting HDAC2 reverse cognitive function and boost memory formation, offering new hope for treating neurodegenerative diseases.
Researchers at Albert Einstein College of Medicine found that an HDAC inhibitor, LBH589, is effective in killing head and neck cancer cells grown in the laboratory. The study identified a set of genes whose expression levels change in response to the drug, which may help doctors identify patients most likely to respond.
A new study by researchers at Children's Hospital of Philadelphia may lead to an emergency treatment for heart attack patients. By targeting gene pathways and inhibiting enzymes, the approach has shown promising results in reducing tissue damage and cell death during ischemia.
Researchers have discovered how HDAC inhibitors specifically damage cancer cells, leading to cell death. The compounds may also cause DNA damage that cannot be repaired, resulting in tumor cell death. However, these inhibitors can also have adverse effects, such as liver damage and metabolic abnormalities.
Researchers at Medical College of Georgia Cancer Center have developed a cancer cell line that is resistant to histone deacetylase (HDAC) and heat shock protein 90 (hsp90) inhibitors, two promising cancer treatments.
A Virginia Commonwealth University research team has received a $1.3 million NCI grant to improve histone deacetylase inhibitors in treating leukemia. The goal is to develop novel combination regimens incorporating these agents with NF-kappa B antagonists.
Researchers develop new therapy to re-activate silenced genes, potentially blocking cell death in stroke patients. The therapy targets histone deacetylase enzymes, which can modulate gene expression and produce neuroprotective proteins.
Researchers found that a drug called trichostatin A can increase SMN2 gene activity, improving symptoms and extending survival in SMA mice. Treatment started after symptoms appeared led to a 19% longer lifespan on average.
A study shows that trichostatin A, a hydroxamic acid HDAC inhibitor, increases SMN2 production in both neural tissues and muscles of mice with spinal muscular atrophy, improving survival chances. The treatment attenuates disease symptoms in affected mice.
Researchers found that combining histone deacetylase inhibitors with anti-angiogenesis drugs reduced tumor growth in mice by up to 85% and controlled new blood vessel formation by 60%. This combination therapy may provide a greater impact on cancer development than using the drugs alone.
Researchers found that HDAC inhibitors promote adult muscle growth and regeneration by stimulating follistatin levels in skeletal muscle tissues. Follistatin is proposed as a potential drug target to regenerate healthy new muscle tissues in animal models of muscular dystrophies.
Researchers found that HDAC inhibitors and DPDTB can inhibit aggresomes formed by mutant SOD protein, suggesting a potential new therapeutic approach for ALS. This study may lead to alleviating ALS symptoms and prolonging life span in transgenic mice models.